Abstract
Introduction: Several studies have related shortened leukocyte telomere length (LTL) with age-related diseases and worse prognosis. Telomere length attrition has recently been associated with inflammatory diseases, including psoriasis (Ps). However, no study has demonstrated an association between LTL and the risk of disease severity and metabolic comorbidities in Arab patients with Ps. Methods: 68 patients with Ps and 42 normal controls were included. LTL and oxidative damage were determined by quantitative (q) PCR. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using logistic regression. Statistical differences between the groups were determined using χ2 and t tests. Results: Patients with Ps had significantly shorter LTL (p = 0.032) and higher oxidative damage (p = 0.015) than those without Ps. Patients with moderate-to-severe index (p = 0.03) and metabolic comorbidity showed significantly shorter LTL (p = 0.003) compared to patients with mild index and without metabolic comorbidity, respectively. Patients with short LTL (≤0.9) were correlated with higher risk of moderate-to-severe conditions (OR = 6.98, 95% CI = 2.3–20.8, p = 0.001) and metabolic comorbidities (OR = 2.89, 95% CI = 1.02–8.2, p = 0.04). Conclusion: LTL shortening may be a consequence of increased oxidative damage and is related to the risk of severe Ps and metabolic comorbidities. Therefore, LTL may be a good candidate biomarker for predicting the risk of poor prognosis in patients with Ps.
Journal Section:
Original Article
References
1.
Rendon
A
, Schakel
K
. Psoriasis pathogenesis and treatment
. Int J Mol Sci
. 2019
;20
(6
):1475
. 2.
Onumah
N
, Kircik
LH
. Psoriasis and its comorbidities
. J Drugs Dermatol
. 2012
;11
(5 Suppl l
):s5
–10
.3.
Sanchez
M
, Kannengiesser
C
, Hoang
S
, Potier
L
, Fumeron
F
, Venteclef
N
, et al. Leukocyte telomere length, allelic variations in related genes and risk of coronary heart disease in people with long-standing type 1 diabetes
. Cardiovasc Diabetol
. 2022
;21
(1
):206
. 4.
Xu
C
, Wang
Z
, Su
X
, Da
M
, Yang
Z
, Duan
W
, et al. Association between leucocyte telomere length and cardiovascular disease in a large general population in the United States
. Sci Rep
. 2020
;10
(1
):80
. 5.
Clemente
DBP
, Maitre
L
, Bustamante
M
, Chatzi
L
, Roumeliotaki
T
, Fossati
S
, et al. Obesity is associated with shorter telomeres in 8 year-old children
. Sci Rep
. 2019
;9
(1
):18739
. 6.
Grunnet
LG
, Pilgaard
K
, Alibegovic
A
, Jensen
CB
, Hjort
L
, Ozanne
SE
, et al. Leukocyte telomere length is associated with elevated plasma glucose and HbA1c in young healthy men independent of birth weight
. Sci Rep
. 2019
;9
(1
):7639
. 7.
Zhang
X
, Zhao
Q
, Zhu
W
, Liu
T
, Xie
SH
, Zhong
LX
, et al. The association of telomere length in peripheral blood cells with cancer risk: a systematic review and meta-analysis of prospective studies
. Cancer Epidemiol Biomarkers Prev
. 2017
;26
(9
):1381
–90
. 8.
Revesz
D
, Milaneschi
Y
, Verhoeven
JE
, Lin
J
, Penninx
BW
. Longitudinal associations between metabolic syndrome components and telomere shortening
. J Clin Endocrinol Metab
. 2015
;100
(8
):3050
–9
. 9.
Blackburn
EH
. Structure and function of telomeres
. Nature
. 1991
;350
(6319
):569
–73
. 10.
Harley
CB
. Telomere loss: mitotic clock or genetic time bomb
. Mutat Res
. 1991
;256
(2–6
):271
–82
. 11.
Kawanishi
S
, Oikawa
S
. Mechanism of telomere shortening by oxidative stress
. Ann N Y Acad Sci
. 2004
;1019
:278
–84
. 12.
Chou
JP
, Effros
RB
. T cell replicative senescence in human aging
. Curr Pharm Des
. 2013
;19
(9
):1680
–98
. 13.
Wu
K
, Higashi
N
, Hansen
ER
, Lund
M
, Bang
K
, Thestrup-Pedersen
K
. Telomerase activity is increased and telomere length shortened in T cells from blood of patients with atopic dermatitis and psoriasis
. J Immunol
. 2000
;165
(8
):4742
–7
. 14.
Chakravarti
D
, Lee
R
, Multani
AS
, Santoni
A
, Keith
Z
, Hsu
WH
, et al. Telomere dysfunction instigates inflammation in inflammatory bowel disease
. Proc Natl Acad Sci USA
. 2021
;118
(29
):e2024853118
. 15.
Wei
D
, Jiang
Y
, Cheng
J
, Wang
H
, Sha
K
, Zhao
J
. Assessing the association of leukocyte telomere length with ankylosing spondylitis and rheumatoid arthritis: a bidirectional Mendelian randomization study
. Front Immunol
. 2023
;14
:1023991
. 16.
Chakravarti
D
, Hu
B
, Mao
X
, Rashid
A
, Li
J
, Li
J
, et al. Telomere dysfunction activates YAP1 to drive tissue inflammation
. Nat Commun
. 2020
;11
(1
):4766
. 17.
Tamayo
M
, Pertega
S
, Mosquera
A
, Rodriguez
M
, Blanco
FJ
, Fernandez-Sueiro
JL
, et al. Individual telomere length decay in patients with spondyloarthritis
. Mutat Res
. 2014
;765
:1
–5
. 18.
Beranek
M
, Borsky
P
, Fiala
Z
, Andrys
C
, Hamakova
K
, Chmelarova
M
, et al. Telomere length, oxidative and epigenetic changes in blood DNA of patients with exacerbated psoriasis vulgaris
. Bras Dermatol
. 2023
;98
(1
):68
–74
. 19.
Gottlieb
AB
, Chaudhari
U
, Baker
DG
, Perate
M
, Dooley
LT
. The national psoriasis foundation psoriasis score (NPF-PS) system versus the psoriasis Area severity index (PASI) and physician’s global assessment (PGA): a comparison
. J Drugs Dermatol
. 2003
;2
(3
):260
–6
.20.
Sobhan
M
, Farshchian
M
. Associations between body mass index and severity of psoriasis
. Clin Cosmet Investig Dermatol
. 2017
;10
:493
–8
. 21.
Alberti
KG
, Zimmet
P
, Shaw
J
. Metabolic syndrome--a new world-wide definition. A consensus statement from the international diabetes federation
. Diabet Med
. 2006
;23
(5
):469
–80
. 22.
Cawthon
RM
. Telomere measurement by quantitative PCR
. Nucleic Acids Res
. 2002
;30
(10
):e47
. 23.
Movassaghi
S
, Jafari
S
, Falahati
K
, Ataei
M
, Sanati
MH
, Jadali
Z
. Quantification of mitochondrial DNA damage and copy number in circulating blood of patients with systemic sclerosis by a qPCR-based assay
. Bras Dermatol
. 2020
;95
(3
):314
–9
. 24.
Lin
PH
, Lee
SH
, Su
CP
, Wei
YH
. Oxidative damage to mitochondrial DNA in atrial muscle of patients with atrial fibrillation
. Free Radic Biol Med
. 2003
;35
(10
):1310
–8
. 25.
Li
J
, An
C
, Zheng
H
, Lei
T
, Zhang
N
, Zheng
Y
, et al. Leukocyte telomere length and risk of papillary thyroid carcinoma
. J Clin Endocrinol Metab
. 2019
;104
(7
):2712
–8
. 26.
Haycock
PC
, Burgess
S
, Nounu
A
, Zheng
J
, Okoli
GN
, Bowden
J
, et al. Association between telomere length and risk of cancer and non-neoplastic diseases: a mendelian randomization study
. JAMA Oncol
. 2017
;3
(5
):636
–51
. 27.
von Zglinicki
T
, Martin-Ruiz
CM
. Telomeres as biomarkers for ageing and age-related diseases
. Curr Mol Med
. 2005
;5
(2
):197
–203
. 28.
Zheng
X
, Wezel
F
, Azoitei
A
, Meessen
S
, Wang
W
, Najjar
G
, et al. Shorter leukocyte telomere length is associated with worse survival of patients with bladder cancer and renal cell carcinoma
. Cancers
. 2021
;13
(15
):3774
. 29.
Ma
H
, Zhou
Z
, Wei
S
, Liu
Z
, Pooley
KA
, Dunning
AM
, et al. Shortened telomere length is associated with increased risk of cancer: a meta-analysis
. PLoS One
. 2011
;6
(6
):e20466
. 30.
Coussens
E
, Grine
L
, Bostoen
J
, Mielants
H
, Lambert
J
. Analysis of telomere length as predictive marker in psoriasis for comorbidities
. Exp Dermatol
. 2016
;25
(5
):388
–90
. 31.
von Zglinicki
T
. Oxidative stress shortens telomeres
. Trends Biochem Sci
. 2002
;27
(7
):339
–44
. 32.
Opresko
PL
, Fan
J
, Danzy
S
, Wilson
DM
3rd, Bohr
VA
. Oxidative damage in telomeric DNA disrupts recognition by TRF1 and TRF2
. Nucleic Acids Res
. 2005
;33
(4
):1230
–9
. 33.
Donati
B
, Valenti
L
. Telomeres, NAFLD and chronic liver disease
. Int J Mol Sci
. 2016
;17
(3
):383
. 34.
Wang
M
. Telomere shortening promotes kidney fibrosis
. Nat Rev Nephrol
. 2021
;17
(6
):368
. 35.
Jonassaint
NL
, Guo
N
, Califano
JA
, Montgomery
EA
, Armanios
M
. The gastrointestinal manifestations of telomere-mediated disease
. Aging Cell
. 2013
;12
(2
):319
–23
. 36.
Rasmy
H
, Mikhael
N
, Ismail
S
. Interleukin-18 expression and the response to treatment in patients with psoriasis
. Arch Med Sci
. 2011
;7
(4
):713
–9
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
